Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30131% above fair value
$236.45−11.32 (-4.57%)
Close on Nov 19, 2026Market cap $15.35BP/E 77.0Yield –
Jazz Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Jazz Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was $1.62B, up 21.3% year over year. For fiscal 2025 it was $1.30B, down 4.5% from the year before. Over ten years it grew 10.1% a year on average. The highest annual figure on record is $1.36B in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30B | -4.5% |
| FY2024 | Dec 31, 2024 | $1.36B | +27.1% |
| FY2023 | Dec 31, 2023 | $1.07B | -14.1% |
| FY2022 | Dec 31, 2022 | $1.24B | +65.5% |
| FY2021 | Dec 31, 2021 | $750.87M | -15.1% |
| FY2020 | Dec 31, 2020 | $884.64M | +20.2% |
| FY2019 | Dec 31, 2019 | $736.27M | -5.4% |
| FY2018 | Dec 31, 2018 | $778.53M | +17.2% |
| FY2017 | Dec 31, 2017 | $664.14M | +14.0% |
| FY2016 | Dec 31, 2016 | $582.70M | +17.5% |
| FY2015 | Dec 31, 2015 | $495.99M | +33.6% |
| FY2014 | Dec 31, 2014 | $371.26M | +33.3% |
| FY2013 | Dec 31, 2013 | $278.46M | +14.2% |
| FY2012 | Dec 31, 2012 | $243.78M | +62.2% |
| FY2011 | Dec 31, 2011 | $150.32M | +158.6% |
| FY2010 | Dec 31, 2010 | $58.14M | – |
| FY2009 | Dec 31, 2009 | -$15.93M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $489.90M | +6.6% |
| Q2 FY2026 | Jun 30, 2026 | $397.60M | +423.8% |
| Q1 FY2026 | Mar 31, 2026 | $388.50M | -6.6% |
| Q4 FY2025 | Dec 31, 2025 | $345.72M | -10.3% |
| Q3 FY2025 | Sep 30, 2025 | $459.50M | +18.4% |
| Q2 FY2025 | Jun 30, 2025 | $75.90M | -76.6% |
| Q1 FY2025 | Mar 31, 2025 | $415.90M | +59.8% |
| Q4 FY2024 | Dec 31, 2024 | $385.29M | +145.0% |
| Q3 FY2024 | Sep 30, 2024 | $387.96M | +28.1% |
| Q2 FY2024 | Jun 30, 2024 | $324.26M | +11.4% |
| Q1 FY2024 | Mar 31, 2024 | $260.33M | -17.8% |
| Q4 FY2023 | Dec 31, 2023 | $157.24M | -52.7% |
| Q3 FY2023 | Sep 30, 2023 | $302.90M | -28.4% |
| Q2 FY2023 | Jun 30, 2023 | $291.03M | +0.1% |
| Q1 FY2023 | Mar 31, 2023 | $316.89M | +61.1% |
| Q4 FY2022 | Dec 31, 2022 | $332.59M | +98.2% |
| Q3 FY2022 | Sep 30, 2022 | $422.89M | +59.1% |
| Q2 FY2022 | Jun 30, 2022 | $290.76M | +742.4% |
| Q1 FY2022 | Mar 31, 2022 | $196.69M | -30.5% |
| Q4 FY2021 | Dec 31, 2021 | $167.79M | -7.9% |
| Q3 FY2021 | Sep 30, 2021 | $265.73M | +4.4% |
| Q2 FY2021 | Jun 30, 2021 | $34.52M | -80.8% |
| Q1 FY2021 | Mar 31, 2021 | $282.83M | +5.5% |
| Q4 FY2020 | Dec 31, 2020 | $182.16M | +125.8% |
| Q3 FY2020 | Sep 30, 2020 | $254.52M | -22.0% |
| Q2 FY2020 | Jun 30, 2020 | $179.83M | +33.3% |
| Q1 FY2020 | Mar 31, 2020 | $268.14M | +38.0% |
| Q4 FY2019 | Dec 31, 2019 | $80.66M | -62.1% |
| Q3 FY2019 | Sep 30, 2019 | $326.42M | +50.1% |
| Q2 FY2019 | Jun 30, 2019 | $134.88M | -28.2% |
| Q1 FY2019 | Mar 31, 2019 | $194.31M | +21.3% |
| Q4 FY2018 | Dec 31, 2018 | $212.95M | +8.8% |
| Q3 FY2018 | Sep 30, 2018 | $217.54M | +20.5% |
| Q2 FY2018 | Jun 30, 2018 | $187.84M | +48.0% |
| Q1 FY2018 | Mar 31, 2018 | $160.21M | -0.5% |
| Q4 FY2017 | Dec 31, 2017 | $195.68M | +9.1% |
| Q3 FY2017 | Sep 30, 2017 | $180.55M | – |
| Q2 FY2017 | Jun 30, 2017 | $126.94M | – |
| Q1 FY2017 | Mar 31, 2017 | $160.97M | – |
| Q4 FY2016 | Dec 31, 2016 | $179.42M | – |
See a number that looks wrong?